The apolipoprotein E ε4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant

Neurology

Volumn 47, Issue 1, 1996, Pages 190-196

  Olichney, J M ^a,c   Hansen, L A ^b   Galasko, D ^a   Saitoh, T ^b   Hofstetter, C R ^a   Katzman, R ^b   Thal, L J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

ALLELE; ALZHEIMER DISEASE; ARTICLE; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENILE PLAQUE; VASCULAR AMYLOIDOSIS; AGED; ANALYSIS OF VARIANCE; GENETICS; GENOTYPE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; GENOTYPE; HUMANS; LEWY BODIES; MALE;

EID: 0029666413     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.1.190     Document Type: Article

References (48)

1. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
2. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ∈4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of Apolipoprotein E Type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 1993;261:921-923.
4. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
5. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
6. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoformspecific interactions of apolipoprotein E with microtubule associated protein tau: implications for Alzheimer's disease. Proc Natl Acad Sci USA 1994;91:11183-11186.
7. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 1994;125:163-171.
8. Cotton P. Constellation of risks and processes seen in search for Alzheimer's clues. JAMA 1994;271:89-91.
9. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 1995;92:763-767.
10. Whitson JS, Mims MP, Strittmatter WJ, Yamaki T, Morrisett JD, Appel SH. Attenuation of the neurotoxic effect of Aβ amyloid peptide by apolipoprotein E. Biochem Biophys Res Commun 1994;199:163-170.
11. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-238.
12. Galasko D, Saitoh T, Xia Y, et al. The apolipoprotein E allele ∈4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology 1994;44:1950-1951.
13. St Clair D, Norrman J, Perry R, Yates C, Wilcock G, Brooks A. Apolipoprotein E ∈4 allele frequency in patients with Lewy body dementia, Alzheimer's disease and age-matched controls. Neurosci Lett 1994;176:45-46.
14. Pickering-Brown SM, Mann DMA, Bourke JP, et al. Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other β-amyloid-forming diseases. Lancet 1994; 343:1155.
15. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E genotype and Lewy body disease. Neurology 1995;45:97-103.
16. Harrington CR, Louwagie J, Rossau R, et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Am J Pathol 1994;145:1472-1484.
17. Hansen LA, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathological entity. Neurology 1990;40:1-8.
18. Olichney JM, Galasko D, Corey-Bloom J, Thal LJ. The spectrum of diseases with diffuse Lewy bodies. In: Weiner WJ, Lang AE, eds. Advances in neurology. Vol. 65. Behavioral neurology of movement disorders. New York: Raven Press, 1995:159-170.
19. Hansen LA, Galasko D, Samuel W, Xia Y, Chen X, Saitoh T. Apolipoprotein-E-∈-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neurosci Lett 1994;182:63-65.
20. Braak H, Braak E. Neuropathological staging of Alzheimerrelated changes. Acta Neuropathol (Berl) 1991;82:239-259.
21. Payami H, Montee KR, Kaye JA, et al. Alzheimer's disease, apolipoprotein E4, and gender. JAMA 1994;271:1316-1317.
22. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995;45:1323-1328.
23. Jarvik GP, Wisjman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-1096.
24. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
25. Mirra SS, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed/rev. Washington DC, 1987.
28. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-895.
29. Wenham PR, Price WH, Blundell G. Apolipoprotein E typing by one-stage PCR. Lancet 1991;337:1158-1159.
30. Hixson J, Vernier D. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhA1. J Lipid Res 1991;31:545-548.
31. Lennox G, Lowe J, Morell K, Landon M, Mayer RJ. Antiubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989;52:67-71.
32. Sanan DA, Weisgraber KH, Mahley RW, et al. Apolipoprotein E associates with amyloid peptide of AJzheimer's disease to form novel monofibrils: isoform ApoE4 associates more efficiently than ApoE3. J Clin Invest 1994;94:860-869.
33. Hyman BT, Rebeck GW, Cristie R, Strickland DK. Apolipoprotein E receptors in the central nervous system [abstract]. Neurology 1995;45(suppl 4):A374.
34. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995;82:331-340.
35. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer's disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
36. Perry RH, Irving D, Blessed G, Fairbairn AF, Perry EK. Senile dementia of the Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
37. Harrington CR, Perry RH, Perry EK, et al. Senile dementia of Lewy body-type and Alzheimer-type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 1994;5:215-228.
38. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541:163-166.
39. Han SH, Hulette C, Saunders AM, et al. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol 1994;128:13-26.
40. Wu E, Lipton RB, Dickson DW. Amyloid angiopathy in diffuse Lewy body disease. Neurology 1992;42:2131-2135.
41. Ferreiro JA, Ansbacher LE, Vinters HV. Stroke related to cerebral amyloid angiopathy: the significance of systemic vascular disease. J Neurol 1989;236:267-272.
42. Gumming AM, Robertson FW. Polymorphism at the apolipoprotein E locus in relation to risk of coronary artery disease. Clin Genet 1984;25:310-313.
43. Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol and coronary artery disease. Clin Chem 1986; 32:778-781.
44. Kussi T, Nieminen MS, Ehnholm C, et al. Apolipoprotein E polymorphism and coronary artery disease: increased prevalence of apolipoprotein E-4 in angiographically defined coronary patients. Arteriosclerosis 1989;9:237-241.
45. Hansen LA, DeTeresa R, Davies P, Terry RD. Neocortical morphometry, lesion counts and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology 1988;38:48-54.
46. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30:572-580.
47. Masliah E, Mallory M, Hansen LA, DeTeresa R, Terry RD. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993;43:192-197.
48. Jaffe AB, Toran-Allerand D, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid β precursor protein. J Biol Chem 1994;13065-13068.